Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab

Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience

“…We have previously reported that rituximab (RTX) is effective in the treatment of orbital pseudolymphoma, a disease characterised by tissue infiltration by CD20+ B lymphocytes 9. Subsequently we reported that orbital pseudolymphoma patients have elevated serum IgG4 levels and tissue infiltration with IgG4-positive cells, leading to the inclusion of orbital pseudolymphoma as a manifestation of IgG4-RD 10.…”

Immunoglobulin G4-Related Disease and the Lung

“…Several reports in recent years have described successful use of rituximab therapy, even in patients who failed to achieve a durable remission with steroid-sparing immunosuppressive agents. 37,[78][79][80][81][82][83][84][85] Recently, Carruthers and colleagues 82 reported the treatment of 30 IgG4-RD patients with 2 doses of rituximab (1000-mg doses administered approximately 15 days apart) in an open-label pilot trial resulting in favorable disease responses in 97% of the participants. The majority of these patients had been treated previously with corticosteroids and steroid-sparing immunosuppressive agents that did not prevent relapse.…”

Treatment: Immunomodulatory Drugs and Rituximab

“…Orbital pseudolymphoma is a condition that was traditionally treated with radiation treatment. However, it has also been demonstrated that treatment with RTX successfully induces remission in most patients [ 11 ]. Subsequent studies demonstrated that many patients with orbital pseudolymphoma frequently have elevated serum IgG4 levels, and now, orbital pseudolymphoma is recognized as a manifestation of IgG4-RD [ 12 ].…”